Out now: The PRISMA 2020 statement, a major update of the 2009 Preferred Reporting Items for Systematic reviews and Meta-Analyses reporting guideline 🥳 In this thread I provide links to the papers and highlight key points 🧵
PRISMA 2020 is published as a suite of three papers: the statement paper, co-published in @bmj_latest @PLOSMedicine @JClinEpi @ijspg and #SysRevsJ presents the updated checklists and flow diagram templates bmj.com/content/372/bm…
The PRISMA 2020 explanation and elaboration paper in @bmj_latest explains why reporting of each item is recommended, presents bullet points that detail the recommendations, and exemplars from published reviews bmj.com/content/372/bm…
The PRISMA 2020 E&E paper also includes boxes describing advances in key components of systematic reviews, such as study selection methods, assessment of risk of bias, meta-analysis and registration of reviews 
The PRISMA 2020 development paper in @JClinEpi outlines the steps taken to update the PRISMA 2009 statement and provides rationale for modifications to the original items authors.elsevier.com/a/1cgSD3BcJQ6%…
PRISMA 2020 is intended for use in systematic reviews with or without meta-analysis or other statistical synthesis methods, and mainly for reviews evaluating effects of interventions, but many items apply to reviews with other objectives
PRISMA 2020 includes guidance on how to report all sections of a review (e.g. objectives, eligibility criteria, search, study selection, data collection, risk of bias assessment, synthesis, results, discussion and declarations)
Compared with the original statement, PRISMA 2020 includes new items on assessing certainty in the body of evidence, competing interests of review authors, and availability of data, code and other materials
We’ve also provided novel guidance on how to report the use of automation tools at various steps of the review process, such as searching, study selection and data collection
In addition to the exemplars in the PRISMA 2020 explanation and elaboration paper, we have a bank of exemplars to illustrate how to report each item, available in the supplement bmj.com/content/372/bm…
We’ll be updating the PRISMA statement website (prisma-statement.org) soon with links to Word templates of the PRISMA 2020 checklists and flow diagrams
If keen to start using the PRISMA 2020 checklists now, try the Shiny App developed by @mcguinlu available at prisma.shinyapps.io/checklist/
And PRISMA 2020 flow diagrams can be generated using a Shiny App developed by @nealhaddaway available at eshackathon.org/software/PRISM…
This was a ton of work done with collaborators with a broad range of expertise in systematic review methods and experience working as or with key end users; this is most of us in 2018 and the smiles continue to this day!
Biggest thanks to my co-leads @jomck15 and @dmoher for their endless guidance and encouragement over the last few years and for giving me the confidence to take this on 🙌
I’ll be presenting a webinar on the PRISMA 2020 statement as part of the Therapeutics Initiative (@Drug_Evidence) Methods Speaker Series at the end of April, details and registration here ti.ubc.ca/2021/03/23/apr…
Finally, I’d like to end by acknowledging Doug Altman and Alessandro Liberati, two giants in evidence-based medicine whose contributions were fundamental to the development of the original PRISMA statement. I hope they’d be proud of us
• • •
Missing some Tweet in this thread? You can try to
force a refresh
